The facility will enable BVI to diversify its product offering from Foot and Mouth Disease (FMD) vaccines to other animal solutions, penetrate new markets and improve its production, warehousing and distribution capacities.
The blending and filling facility meets international vaccine standards set by the World Organization for Animal Health (WOAH) as well as to Good Manufacturing Practice (GMP), which will enable BVI to not only expand its product range but also gain access to new lucrative international markets.
BVI general manager Andrew Madeswi, said the “Four for Forty” strategic goal is part of BVI’s 2021-25 strategic plan, which seeks to re-energise BVI as a key player in unlocking Africa’s vast livestock potential by ensuring sustainable growth and profitability; and boosting operational efficiency.
“BVI simply wants to reduce reliance on FMD vaccines by ensuring that 40 % of our total revenue is generated from at least four non-FMD products,” said Madeswi.
The Institute also has plans to develop one of the biggest antigen banks in Africa, with a view to increasing recurring revenue and reducing delivery lead time. According to Madeswi, BVI can only remain globally competitive by ensuring competitive supply of high-quality products at adequate levels of complexity and agility.
“Quality will be assured through strict adherence to international standards, sound quality management systems and a customer-centric approach. As a global player in the manufacture and distribution of vaccines, BVI must meet evolving market demands and position itself as a centre of excellence in research and development,” he said
